Molecular epidemiological characteristics of carbapenem-resistant Pseudomonas aeruginosa clinical isolates in southeast Shanxi, China

Journal of Global Antimicrobial Resistance, Journal Year: 2024, Volume and Issue: 36, P. 301 - 306

Published: Jan. 23, 2024

: Infection by carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a serious clinical problem worldwide. However, the molecular epidemiology of isolates varies depending on region. This study was conducted to analyze resistance phenotype and clarify genetic epidemiological properties CRPA from southeast Shanxi, China. Methods: Fifty-seven were collected hospital in this These re-identified MALDI-TOF subjected whole-genome sequencing next-generation sequencing. Phylogenetic trees constructed based single nucleotide polymorphisms (SNPs), after which multilocus sequence typing (MLST) performed antimicrobial genes identified. All 57 carried at least one kind gene encoding carbapenemase, such as blaIMP-1, blaIMP-10, blaOXA-10, blaOXA-395, blaOXA-396, blaOXA-485, blaOXA-486, blaOXA-488, blaOXA-494, blaOXA-50. The harbored AIM-1, CMY-51, mecD, NmcR Pseudomonas-derived cephalosporinase (PDC) β-lactamase-encoding gene, blaPCD-1 blaPCD-3, blaPCD-5, or blaPCD-7 blaPCD-10. Two found harbor aminoglycoside-modif ying enzyme aadA1 aadA7; however, no 16S rRNA methylase quinolone resistance-related genes. belonged various types (STs), two which, namely, ST235 ST277, high-risk types. Our findings indicate that carrying with unique regional characteristics are spreading region, high diversity STs, especially clones. highlight necessity for further measures prevent spread Shanxi.

Language: Английский

---

High ceftazidime-avibactam resistance among carbapenem-resistant Enterobacter species: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2014–2021

International Journal of Antimicrobial Agents, Journal Year: 2024, Volume and Issue: 63(4), P. 107105 - 107105

Published: Feb. 6, 2024

Language: Английский

---

Ceftazidime-Avibactam as a Salvage Treatment for Severely Infected Immunosuppressed Children

Drug Design Development and Therapy, Journal Year: 2024, Volume and Issue: Volume 18, P. 3399 - 3413

Published: July 1, 2024

Background: Multidrug-resistant Gram-negative bacteria (MDR-GNB) are becoming increasingly common around the world, with carbapenems frequently serving as a last resort but being threatened by growing incidence of carbapenemase-producing bacteria. Ceftazidime-avibactam (CAZ/AVI) is potential agent against MDR-GNB limited clinical experience, particularly in critically ill immunosuppressed children. Methods: This study analyzed use CAZ/AVI salvage treatment severely infected children from September 2019 to July 2022. Patients confirmed GNB infection who received were matched patients other antibiotics. Results: Twenty-five treated included. The majority had hematologic diseases. All presented sepsis all 30 courses. Septic shock 36.7% these primary sites included bloodstream (20.0%), skin and structure intra-abdominal (13.3%) hospital-acquired pneumonia (10.0%). Twelve 25 (48.0%) positive microbiological cultures, mainly Pseudomonas aeruginosa Klebsiella pneumoniae , including 5 carbapenem-resistant GNB-infected cases. Fifteen (50.0%) courses improvement. For initial course each patient, response rate recovered group was significantly higher than that without recovery (66.7% vs 23.1%, P = 0.047). 14-day 30-day mortality rates 24.0% 28.0%, respectively, which correlated absence ( 0.004 0.024, respectively) site 0.001 0.006, respectively). There no significant difference major outcomes between Conclusion: could be considered strategy for infection. Caution should taken when applied recovery. Keywords: gram-negative bacteria, hematological disease, hematopoietic stem cell transplantation, adverse events

Language: Английский

---

Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam

Journal of Family Medicine and Primary Care, Journal Year: 2025, Volume and Issue: 14(1), P. 311 - 316

Published: Jan. 1, 2025

A BSTRACT Background: Multidrug resistant (MDR) Gram negative organisms are becoming increasingly common. Carbapenem Enterobacterales (CRE) pose a major threat and necessitate the development of new antibiotics. MDR carbapenem infections, which common in intensive care units hospitals, lead to increased morbidity, mortality, prolonged hospital stays, higher healthcare costs. New antimicrobials such as ceftazidime avibactam offer potential alternatives conventional treatments tigecycline colistin, have significant side effects limitations. Aim: This study focuses on antibiotic susceptibility ceftazidime/ bacilli found large number clinical samples collected from tertiary facility Netaji Subhas Medical University Hospital, Bihta, India. Methodology: The included 81 bacteria isolated patient samples. Based Clinical Laboratory Standards Institute guidelines mentioned Kirby Bauer disc diffusion method. Result Conclusion: results showed that inhibited 89.9% Enterobacteriaceae isolates, was than 80.3% amikacin 85.1% meropenem. Ceftazidime effective against CRE isolates 69.9% cases urine 94% cases, 40% ceftriaxone nitrofurantoin. show can cure especially urinary tract better antibiotics, is great help fight increasing resistance.

Language: Английский

---

Re: ‘Mortality due to carbapenem-resistant Acinetobacter baumannii bacteraemia’ by Kritsotakis et al.

Clinical Microbiology and Infection, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский

---